A comprehensive literature review was performed to evaluate the effect of various hormonal therapies, in terms of variations of intestinal and pain complaints and of patient satisfaction with treatment, in women with symptomatic, non-severely sub-occlusive endometriosis infiltrating the proximal rectum and sigmoid colon. A MEDLINE search through PubMed from 2000 to 2018 was conducted to identify all original English language articles published on medical treatment for colorectal endometriosis. Additional reports were identified by systematically reviewing reference lists and using the "similar articles" function in PubMed. A total of 420 women with colorectal endometriosis treated with combined oral contraceptives, progestins, gonadotropin releasing-hormone (GnRH) agonists and aromatase inhibitors have been described in eight case series, two retrospective cohort studies and four case reports. Published data consistently suggest that several hormonal medications can control most symptoms associated with intestinal endometriosis, provided the relative bowel lumen stenosis is less than 60%. Patients with irritative-type symptoms appear to respond better than those with constipation. Overall, about two-thirds of women were satisfied with the treatment received, independently of the drug used. Progestins are the compound supported by the largest body of evidence. The addition of aromatase inhibitors or, alternatively, the use of GnRH agonists does not seem to be associated with better outcomes. Long-term treatment with a progestin should be proposed as an alternative to surgery to patients with nonseverely sub-occlusive endometriosis infiltrating the proximal rectum and sigmoid colon who are not seeking conception. The final decision should be shared together with the woman, respecting her preferences and priorities.
Introduction
Deep bowel endometriosis, i.e. endometriosis infiltrating the intestinal muscular layer (1), appears to affect about one tenth of women with the endometriotic disease (2, 3) . When endometriosis causes bowel obstruction or severe sub-occlusion, surgery is the only reasonable choice. However, most patients with deep bowel endometriosis complain of cyclic and non-cyclic symptoms, such as abdominal bloating, intestinal cramping, diarrhea and constipation, without obvious obstruction to stool passage (Figures 1 and 2 ). Symptoms may be associated not only with the degree of endometriotic infiltration and bowel lumen restriction but also with lesion localization (1, 4) . The rectosigmoid colon is the most frequently involved intestinal tract, followed by isolated nodules of the proximal sigmoid and by lesions of the terminal ileus and cecum (3, 5, 6) .
According to some authors, excisional surgery is the best solution for women with symptomatic intestinal endometriosis, as medical treatments may exert an effect on the endometrial and smooth muscle component of the nodule, but not on the extensive fibrotic component, thus providing limited benefit (3, (7) (8) (9) . However, several investigators observed substantial improvements of bowel symptoms during hormonal treatment (10) (11) (12) (13) (14) . Disentangling the uncertainties of the role of medical therapy in women with infiltrating bowel endometriosis seems exceedingly important, as excisional procedures with opening of the bowel lumen are generally effective in relieving intestinal symptoms but are also associated with severe short-and long-term complications in about one of 10 patients (for example, intestinal leakage, anastomosis dehiscence, septic peritonitis, rectovaginal fistula formation, bowel anastomosis stenosis, iatrogenic neurologic bladder dysfunction with need for long periods of selfcatheterization, and postoperative constipation and de novo rectal dysfunction) (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) . The incidence of some complications is associated also with the distance between the lower margin of resection and the anal verge (9, 26) . Thus, defining the localization of the lesion is important for limiting selection bias when comparing treatments in a research setting, and for counseling women when taking a decision in a clinical setting (9, (15) (16) (17) (18) (19) (20) 26, 27) .
Given this background and the lack of consensus regarding the role of hormonal treatments for bowel endometriosis, we deemed it opportune to synthetize the available evidence on the outcome of various medical therapies that have been used in patients with symptomatic, non-severely sub-occlusive lesions. As hormonal treatments for endometriosis generally suppress ovulation (28) , the findings presented in this review may be used to inform and counsel specifically women not seeking conception.
Material and methods
The objective of the present comprehensive review was the evaluation of the effect of various hormonal therapies, in terms of variations of intestinal and pain complaints as well as of patient satisfaction with treatment, in women with symptomatic colorectal endometriosis.
The aim was to identify reports of studies including patients with an instrumental diagnosis of endometriosis infiltrating the muscular layer of the proximal rectal tract (≥8 cm from the anal verge), the rectosigmoid junction (13-15 cm from the anal verge) and the sigmoid (>15 cm from the anal verge). Studies focusing specifically on nodules of the distal rectum (within 8 cm from the anal verge) were not considered, as these lesions constitute part of rectovaginal endometriotic plaques (29) . Stenotic occlusion of the rectal ampulla is exceedingly rare due to its large caliber and distensibility. Moreover, in contrast to the proximal third of the rectum (upper rectum), the mid-rectum, which corresponds to the Douglas pouch, only has an anterior peritoneal covering. This renders sharp angulation, a determinant of bowel occlusion caused by endometriosis, mechanically unlikely if not impossible (15) . In addition, the symptoms associated with endometriotic nodules of the mid-/low-rectum are dyschezia and tenesmus, which are specific of lesions of the ampulla (30) . Owing to the clinical differences with other endometriotic lesions of the proximal large bowel tract, the effect of medical therapies on nodules of the distal rectum has been already reported separately in another review (31) .
A MEDLINE search through PubMed from January 2000 to January 2018 was conducted using combinations of medical subject heading terms "colorectal endometriosis", "intestinal endometriosis", "bowel endometriosis", "medical treatment", "combined oral contraceptives", "progestins", "GnRH agonists", "danazol" and "aromatase inhibitors". Only articles written in English and published in peer-reviewed journals were included, and the relative reference lists were systematically reviewed to identify further reports. Additional articles were searched using the "similar articles" function in PubMed. Information was extracted on study design, number of treated patients, type of intestinal lesions, type of hormonal drugs used, treatment period, adverse events, types of questionnaires administered to assess bowel symptoms and function, and overall clinical outcome.
Results
A total of 420 women with large bowel endometriosis treated with combined oral contraceptives (OC), progestins, gonadotropin releasing-hormone (GnRH) agonists, and aromatase inhibitors have been described in 14 articles published in 2000-2018. Eight studies were case series (seven prospective, one retrospective) (10) (11) (12) (13) (14) (32) (33) (34) , two were retrospective cohort studies (29, 35) and four were case reports (36-39) ( Table 1 ). The precise location of lesions has not been systematically specified, and sometimes what was exactly intended with "colorectal endometriosis" is unclear. This terminology appears to have been used for different clinical situations, not exclusively in cases of sigmoid and recto-sigmoid junction endometriosis, but also in cases of rectal nodules, which should be more properly included in the category of rectovaginal lesions or Douglas pouch lesions infiltrating the anterior rectal wall (15, 29, 31) . The duration of medical treatment was three months in two studies, six months in three, 12 months in five, and >12 months in four, including the two cohort studies.
Estrogen-progestins and progestins
Ferrari et al. (12) treated 26 patients with colorectal endometriotic lesions infiltrating the tunica muscularis with a low-dose, monophasic OC used continuously for 12 months. The lesion, as assessed at rectal endoscopic ultrasonography, was within 5 cm from the anal rim in four cases, between 5 and 10 cm in 14, and above 10 cm in eight. Women with an intestinal lumen stenosis more than 50% were excluded. Symptoms progressively improved and the nodule volume decreased by 62% at the end of the study. At the 1-year evaluation, 18 patients (69%) were satisfied or very satisfied with their treatment, four were uncertain, and four were dissatisfied or very dissatisfied. Millochau et al. (38) reported the case of a woman treated with estrogen-progestin combinations for an isolated nodule of the sigmoid colon that grew during a 4-year medical treatment, causing occlusive symptoms and necessitating surgery.
Egekvist et al. (35) conducted a retrospective cohort study in one of the two Danish tertiary referral centers in which treatment of advanced endometriosis is allowed by the national health authority. Patients treated medically or surgically for rectosigmoid lesions were identified in the electronic patient record system according to ICD10 codes for endometriosis affecting the rectosigmoid, vagina or the rectovaginal septum. Of the 238 women with rectosigmoid endometriosis verified by transvaginal ultrasonography and/or magnetic resonance imaging, 78 (33%) underwent immediate surgery, whereas 160 were treated medically with OCs, a levonorgestrel-releasing intrauterine device, or oral progestins. After a median follow-up of 22 months, 27 of the 160 (17%) patients initially treated medically, required surgery. Overall, 133/238 (56%) women with rectosigmoid endometriosis could be managed successfully with hormone manipulation, and about four of five women (133/160; 83%) for whom a medical treatment was decided at baseline evaluation, eventually avoided surgery.
The largest evidence on the effect of progestins for bowel endometriosis is derived from studies on the use of norethisterone acetate (NETA) and dienogest. Ferrero et al. (11) enrolled 40 patients with nodules infiltrating the sigmoid (n = 18), the recto-sigmoid junction (n = 12) and the rectum (n = 10). The diagnosis was based on multidetector computed tomography enteroclysis, and women with a stenosis of the bowel lumen greater than 60% were excluded. Norethisterone acetate determined relief from symptoms related to the menstrual cycle, including constipation, diarrhea and cyclical rectal bleeding. The severity of diarrhea, intestinal cramping and passage of mucus also significantly improved during 16 women with rectovaginal or bowel endometriosis with dienogest, 2 mg/ day for six months. All participants had already used other progestins without improvement of pain. It is unclear whether all the participants had intestinal lesions and the exact lesion locations. The mean volume of the intestinal nodule decreased from 3.4 cm 3 at baseline to 1.6 cm 3 at the end of treatment. A significant reduction in defecation pain, reported by 69% of the patients at baseline, was observed from the second month of therapy.
Leonardo-Pinto et al. (14) evaluated the effect of dienogest prescribed for 12 months in 30 women with rectovaginal and bowel endometriosis. At baseline, participants reported persistent pain complaints despite medical treatment with other progestins for at least 6 months. In this study as well, it was not specified whether all the patients had intestinal lesions or the level of the lesions. Intestinal pain decreased significantly during the study period but, at odds with their previous experience (35), the authors did not observe a significant reduction in bowel lesion size.
Dienogest was also used by Tamura et al. (37) and Ng et al. (39) in two women with endometriosis located at the proximal rectum and rectosigmoid junction. Substantial bowel symptom improvement and lesion size reduction were observed in both patients after progestin treatment, respectively, for 22 and six months.
A parallel cohort study was conducted on 87 women with colorectal endometriosis not causing persistent and severe sub-occlusive symptoms, to investigate whether an OC and a progestin are satisfactory alternatives to surgery in women who choose their treatment after a standardized shared decision-making process (29) . A total of 50 patients chose treatment with a low-dose, monophasic OC (n = 12) or a progestin (norethisterone acetate, 2.5 mg/day or dienogest, 2 mg/day; n = 38) and 37 women confirmed the previous indication to surgery. Six women in the medical treatment group requested surgery because of drug inefficacy or intolerance. Seven major complications (19%) were observed in the surgery group. At the 12-month follow-up, 39 (78%) women in the OC/progestin group were satisfied with their treatment, compared with 28 (76%) in the surgery group (intentionto-treat analysis). Corresponding figures after a median follow-up of, respectively, 40 and 45 months, were 72% in the former group and 65% in the latter one. The 60-month cumulative proportion of dissatisfaction-free participants was 71% in the OC/progestin group compared with 61% in the surgery group. Bowel symptoms were improved by both treatments.
GnRH agonists
Porpora et al. (36) treated a woman with sigmoid endometriosis with leuprolide acetate in a monthly depot formulation and observed symptom remission and lesion disappearance at 6-month follow-up colonoscopy.
The effect of a GnRH agonist (triptorelin in a depot three-monthly formulation) with add-back therapy (oral tibolone, 2.5 mg/day) for 12 months was assessed by Ferrero et al. (10) in 18 women with endometriotic nodules infiltrating the sigmoid (n = 9), the recto-sigmoid junction (n = 5) and the rectum (n = 4). The larger colorectal nodule had a mean diameter of 2.2 AE 0.6 cm and the mean degree of stenosis of the bowel lumen was 42.0 AE 9.7%. Intestinal symptoms improved during treatment in 11 (61%) women, whereas in seven (39%) the intestinal function did not change. In particular, patients with symptoms mimicking diarrhea-predominant irritable bowel syndrome benefitted more from GnRH agonist treatment compared with those complaining of symptoms mimicking constipation-predominant irritable bowel syndrome. In fact, abdominal bloating, intestinal cramping and passage of mucus improved but a feeling of incomplete evacuation did not vary. At the 1-year evaluation, 13 (72%) women were satisfied with their treatment.
Roman et al. (34) evaluated the effect of one i.m. depot injection of triptorelin 11.25 mg plus one daily dose of percutaneous estradiol 0.1% as a preoperative measure in 70 patients with an endometriotic rectal nodule infiltrating at least the muscular layer and up to 15 cm above the anus. The rectal lesions were identified at endo-rectal ultrasonography, and a computed tomography-based virtual colonoscopy was performed to identify bowel lumen stenosis and additional intestinal tract localizations. After 3 months of therapy, cyclic digestive complaints were relieved in more than half of the women (defecation pain, 57%; abnormal frequency of bowel movements, 43%; bloating, 36%), whereas constipation and non-cyclic symptoms were improved in less than a third of patients. Subjective improvement was unrelated to rectal nodule volume.
Aromatase inhibitors
An aromatase inhibitor was used by Ferrero et al. (32) in six women with bowel nodules infiltrating at least the tunica muscularis but with lumen stenosis less than 60%. Four patients complained of intestinal cramping, three of abdominal bloating, three of symptoms mimicking irritable bowel syndrome (for example, diarrhea), two of constipation, two of passage of mucus in the stools and one of cyclic rectal bleeding. The patients received oral letrozole (2.5 mg/day) combined with NETA (2.5 mg/day) to prevent ovarian stimulation. All symptoms improved during the 6-month treatment, except constipation. At final assessment, four women (67%) were satisfied with the treatment received and declared that gastrointestinal symptoms were improved.
Discussion
Compared with superficial peritoneal endometriosis, deep endometriosis has a distinct histological characteristic as smooth muscle fibers are also present, in addition to the ectopic endometrial-like mucosa (endometrial epithelium and stroma) and the fibrotic component deriving from inflammation (caused by the metabolic activity of the ectopic endometrium and repeated micro-hemorrhages) (44) . This is expected because the so-called deep endometriosis infiltrates the wall of hollow viscera such as the bowel, the bladder, the ureter and the vagina. The result is a sort of desmoplastic lesion in the form of nodules or plaques comprising the three constituents, the mucosal, the fibrotic and the smooth muscular (44) . If the smooth muscular component is the histologic hallmark of deep endometriosis, we consider as "deep" those forms of bowel endometriosis that infiltrate at least the muscular layer of the considered intestinal tract (1).
Responsiveness to gonadal steroids of the endometrium within deep bowel lesions is the prerequisite for medical therapy aimed at inducing metabolic quiescence of ectopic glands. No€ el et al. demonstrated that progesterone receptors were present in major histologic components of colon endometriosis, including the smooth muscle fibers (45) . Thus, hormonal treatments should exert an effect on two of the three components of deep endometriosis, that is, the ectopic endometrial mucosa and the smooth muscle fibers infiltrated by it. On the other hand, a major effect of medical therapies on the fibrotic component appears unlikely, although an influence of progestins on fibrosis remodeling over time cannot be excluded, due to their demonstrated anti-inflammatory properties (46, 47) .
Two pathogenic mechanisms explain pain associated with deep endometriotic lesions: chronic inflammation deriving from the metabolic activity of ectopic endometrium and secondary fibrosis with embedding of endometriotic glands in scar tissue (15, 30) . Recurring release of mediators of inflammation, such as prostaglandins and cytokines, may cause a functionaltype, mostly cyclic pain, such as irritative-type intestinal symptoms, whereas occlusive-type intestinal symptoms are generally the mechanical consequence of fibrotic tissue retraction; however, they may also be influenced by inflammatory changes of bowel wall nodules (3,6,7) .
Overall, the quality of the evidence on the effect of hormonal therapies as an alternative to surgery for symptomatic bowel endometriosis is suboptimal. Most of the studies available are non-comparative. Moreover, diverse compounds or combinations of compounds have been used with very different durations of treatment. The exact location of intestinal endometriosis was not systematically indicated. Outcomes have been measured using different questionnaires and scales, thus rendering comparisons difficult. Scoring systems to measure pelvic dysfunction and quality of life in women with endometriosis should be standardized (48) . Good-quality, comparative effectiveness research is seriously needed to define more precisely the respective impact of medical treatment and extirpative surgery in the long-term management of patients with symptomatic bowel endometriosis. In the words of Riiskjaer et al. (48) : "the indication for surgery in bowel endometriosis is almost always relative" and "this makes selection of indications for surgery and comparison of treatment modalities and results important".
With this aim, randomized, controlled trials may appear preferable, but adequately designed, prospective parallel cohort studies may also be conducted, especially when women are not prone to receive such diverse treatments at random, and prefer to take part in the medical decision by choosing their preferred alternative based on their priorities after detailed and impartial information has been provided (29, 49) . In fact, the two options cannot be considered at the same level, because the respective balances between potential benefits and potential harms are hardly comparable in the absence of severe sub-occlusion, thus questioning the therapeutic equipoise that is ethically needed for randomization. On the other hand, the shared decision-making may be unduly influenced by the physician's empathy, own beliefs and a priori conviction, thus potentially undermining the scientific foundation on which the process should be based.
In everyday practice the real query may not be which of the two treatments is more effective in absolute terms, but instead to what extent a satisfactory improvement of bowel symptoms is achievable with medical therapy when surgery is considered the standard treatment and, consequently, what is the probability of undergoing surgery anyway because of failure of hormonal manipulation. In this regard, the cohort studies by Egekvist et al. (35) and Vercellini et al. (29) are encouraging, as the majority of patients who used hormonal medications on a long-term basis eventually avoided surgery and were satisfied with their treatment, as pain and bowel symptoms substantially improved.
In spite of the limited quantity and quality of the findings provided in published reports, and while waiting for future better-designed studies, the data included in the present review constitute the only available evidence on which patients and caring gynecologists can currently base their shared decisions. Medical treatment for bowel endometriosis may constitute a therapeutic alternative when established intestinal fibrotic stenosis with severely sub-occlusive symptoms are absent (2, 3, 6) . Bowel occlusion is likely when wall infiltration is associated with intestinal fixed, strict angulation, or when the lumen is intrinsically narrow, such as in cases of involvement of the last ileal loop and the ileocecal valve (50, 51) . The practical issue here is defining when medical therapy is advantageous over surgery, taking into consideration that, if chosen, hormonal treatments should be continued for many years, as drugs control endometriosis but do not definitively cure it (28, 31) . In this regard, the untoward effects of different medications should be adequately described. As an example, progestins are frequently associated with bloating, weight gain and irregular bleeding, especially in women with uterine adenomyosis. This may adversely impact on treatment adherence and, in the long-term, induce patients to request surgery. This important aspect must be clarified during counseling, together with the fact that conservative surgery as an isolated measure also does not guarantee definitive symptom relief (19, 20, 52) .
Published data consistently suggest that several hormonal medications can control most symptoms associated with colorectal endometriosis, provided the relative bowel lumen stenosis is less than 60% (10) (11) (12) 29, 32) . In particular, patients with irritative-type symptoms appear to respond significantly better than those with constipation, which may originate also from altered innervation. The resolution of cyclic inflammation due to intra-and perilesional micro-hemorrhages may explain the effect on irritative complaints, and the observed decrease in nodule size under medical treatment may partially relieve the reduction in lumen caliber of the affected bowel tract. Overall, about two-thirds of women were satisfied with the treatment received, independently of the drug used. The compound progestin is supported by the largest body of evidence. The addition of aromatase inhibitors or, alternatively, the use of GnRH agonists, does not seem to be associated with better outcomes. Given the similar efficacy of the various drugs evaluated in women with colorectal endometriosis, priority should be given to safety, tolerability and costs when choosing among different medical alternatives. In this regard, progestins appear to offer the best overall therapeutic profile, especially considering that medications may be used for very long periods of time.
Recently, Casper questioned the role of OCs in the management of endometriosis based on the hypothesis that, owing to the supra-physiologic estrogen content, these combinations may not adequately suppress lesions and control symptoms (46) . Although some literature data suggest that OCs may be safely used in women with colorectal endometriosis (12, 29) , bowel occlusion during treatment with estrogen-progestin combinations has been reported (38) . Therefore, when treating women with symptomatic intestinal endometriosis, it may be wiser to use progestin monotherapies rather than OCs to minimize the risk of occlusion, (31) . An algorithm for the management of non-occlusive colorectal endometriosis is suggested (Figure 3) , based on the idea that, in women not seeking a natural conception, medical treatment may be considered as the first line of treatment, with surgery reserved to those patients not responding to, not tolerating or with contraindications to progestins.
Medical therapy must be evaluated with caution when managing women who will seek a conception in the short-term. In fact, some cases of large bowel occlusion or perforation as well as hydroureteronephrosis have been reported during pregnancy (53) (54) (55) . Thus, the hormonal milieu of gestation may not guarantee the same lesion control usually observed during medical treatment. Surgery should be also discussed before undertaking in vitro fertilization, as similar complications have been observed during ovarian stimulation (56, 57) . Abdominal procedures for complicated colorectal endometriosis in the presence of a gravid uterus may reveal technically demanding and risky for both the mother and the fetus (58, 59) . Thus, women with sub-occlusive forms seeking pregnancy in the future should be thoroughly informed about the risks of not undergoing prior bowel surgery and should be referred to tertiary care endometriosis centers where expert abdominal surgeons are available for pre-conception evaluation and advice. Unfortunately, except for bowel occlusion, there is currently no robust evidence demonstrating that prophylactic surgery substantially reduces the risk of other major complications during in vitro fertilization and pregnancy.
In conclusion, long-term treatment with a progestin should always be included among the therapeutic options for women with non-severely sub-occlusive bowel endometriosis who are not seeking conception. Given the dramatically different safety profiles, medical treatment and surgery may not be proposed as an "either/or" decision, but rather as a "step-up" decision, where surgery may be indicated as a second step only in those patients not responding to, not tolerating or with contraindications to progestins. Women should be informed in detail about the potential benefits and potential harms of undergoing surgical removal of intestinal endometriosis and of attempting long-term lesion and symptom control with medical therapies (60) . The final decision should be shared together with the woman, respecting her preferences and priorities.
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